Navigation Links
ABR-Affinity BioReagents to Participate in the American Association for Cancer Research Meeting in San Diego, California, April 12 - 16, 2008
Date:4/11/2008

DENVER, and GOLDEN, Colo., April 11 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today its continued support for the American Association for Cancer Research (AACR) and will exhibit at the annual meeting taking place at the San Diego Convention Center, April 12 - 16, 2008.

"The AACR meeting is a highlight of the year for ABR as we devote a significant portion of our corporate resources to supporting biological research in this critically important area," said Ken Wilczek, President of ABR-Affinity BioReagents. ABR's product portfolio includes over 3,000 quality guaranteed cancer biology antibodies. "Attendance at this meeting affords us the opportunity to enhance our understanding of what today's researchers are focusing on in terms of potential targets and timelines. Each year there are an increasing number of significant developments contributing to extraordinary advances in cancer-related disease research. This is just a great forum in which to interact on a personal level with a cross section of the top life science researchers in the U.S. and around the world. We derive much of our strategic direction from this type of input," finished Mr. Wilczek.

ABR-Affinity BioReagents will be launching 7,500 new products at the meeting across a selection of research areas including: Apoptosis; Cancer Biology; Heat Shock Protein; Ion Transport/Regulation; Neurobiology; Signal Transduction; Transcription Regulation; and Vision.

ABR will be located at booth #820 at next week's meeting in San Diego.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).

With more than 35,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry-research antibodies that are 100% quality guaranteed or your money back-with no questions asked.

Utilizing a distribution network encompassing over 55 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
2. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
3. ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
4. ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
5. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
6. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
10. Vicus Therapeutics Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
11. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):